Last edition
News about "Active Psoriatic Arthritis"
The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.
Active Psoriatic Arthritis | 17/03/2026 | By News Bureau
US FDA Clears Sotyktu for Active Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved Sotyktu, developed by Bristol Myers Squibb, for adults with active psoriatic arthritis. The once-daily oral TYK2 inhibitor showed significantly higher ACR20 response rates versus placebo in the phase-III POETYK PsA-1 and PsA-2 trials.
Active Psoriatic Arthritis | 07/03/2026 | By News Bureau | 114
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy